(NASDAQ: HBIO) Harvard Bioscience's forecast annual revenue growth rate of 5.66% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 11.69%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.28%.
Harvard Bioscience's revenue in 2026 is $85,531,000.On average, 4 Wall Street analysts forecast HBIO's revenue for 2026 to be $407,594,168, with the lowest HBIO revenue forecast at $390,726,087, and the highest HBIO revenue forecast at $420,529,370.
In 2027, HBIO is forecast to generate $433,356,327 in revenue, with the lowest revenue forecast at $408,406,000 and the highest revenue forecast at $454,626,346.